CPT Editorial Panel

Myriad remains bullish about its business expansion and revenue growth prospects, despite several ongoing events outside its control that stand to impact its business.

The AMA's CPT Editorial Panel held a meeting in which stakeholders continued ongoing discussions regarding a new CPT coding structure in the works for molecular diagnostics and genetic tests. The new coding structure is expected to take hold in 2012.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.